JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wood, P. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wood, P. L.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*DIAZEPAM
*DOPAMINE
*MUSCIMOL

Actions of GABAergic agents on dopamine metabolism in the nigrostriatal pathway of the rat

PL Wood

The gamma-aminobutyric acid (GABA) transaminase inhibitor aminoxyacetic acid, diazepam and the GABA agonists muscimol, 4,5,6,7- tetrahydroisoxazolo-[5,4-C]-pyridin-3-ol, kojic amine and SL-76002 all depressed nigrostriatal dopamine release as measured by decreased 3- methoxytyramine after parenteral administration. Experiments with intrastriatal and intranigral injections as well as parenteral injections in acutely hemisected and kainate lesioned animals demonstrated that parenteral muscimol inhibits the nigrostriatal pathway at the level of the substantia nigra. In contrast, parenteral 4,5,6,7-tetrahydroisoxazolo-[5,4-C]-pyridin-3-ol, kojic amine and aminoxyacetic acid inhibit the nigrostriatal pathway acting both within the substantia nigra and on presynaptic nigrostriatal GABA receptors in the striatum. A unique interneuronal GABA receptor also appears to be present in the striatum which is activated by intrastriatal muscimol but not 4,5,6,7-tetrahydroisoxazolo-[5,4-C]-pyridin-3-ol or kojic amine. Activation of these receptors leads to increased dopamine release in the striatum; however, this receptor population does not appear to be stimulated after parenteral administration of GABAergic agents. In summary, multiple GABA receptors appear to be present within the central nervous system which possess differential sensitivities to the GABA agonists examined; however, after parenteral administration, all GABAergics appear to depress nigrostriatal dopaminergic transmission.

Volume 222, Issue 3, pp. 674-679, 09/01/1982
Copyright © 1982 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
J PsychopharmacolHome page
A. Delini-Stula and D. Berdah-Tordjman
Benzodiazepines and GABA hypothesis of schizophrenia
J Psychopharmacol, January 1, 1995; 9(1): 57 - 63.
[Abstract] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1982 by the American Society for Pharmacology and Experimental Therapeutics.